HMGB1和GPX3在甲状腺癌中的变化及其与病理特征的关系

Changes of HMGB1 and GPX3 in thyroid cancer and their relation with pathologic characteristics

目的探讨血浆高迁移率蛋白1(HMGB1)、谷胱甘肽过氧化物酶(GPX3)在甲状腺癌中的变化及其与病理特征的关系。方法应用酶联免疫吸附试验(ELISA)测定甲状腺癌组(153例)、甲状腺良性结节组(120例)及健康对照组(120例)血浆HMGB1、GPX3水平,分析血浆HMGB1、GPX3在甲状腺癌患者中的变化;应用受试者特异性曲线(ROC)分析血浆HMGB1、GPX3在甲状腺癌中的应用价值。结果甲状腺癌组血浆HMGB1、HMGB1水平及其阳性表达率均高于甲状腺良性结节组及健康对照组(P<0.05),血浆GPX3水平及GPX3阳性表达率低于甲状腺良性结节组及健康对照组(P<0.05)。甲状腺良性结节组及健康对照组血浆HMGB1、GPX3水平及HMGB1、GPX3阳性表达率比较均差异无统计学意义(P>0.05)。甲状腺癌血浆HMGB1表达与浸润程度、TNM分期、淋巴转移有密切关系(P<0.05),GPX3表达与TNM分期及淋巴结转移有关(P<0.05)。经ROC分析可知,HMGB1、GPX3在甲状腺癌中诊断灵敏度及特异度分别为76.3%、85.5%、70.8%和82.2%。结论血浆HMGB1、GPX3表达水平与甲状腺癌发生及病情进展有密切关系。

Objective To investigate the changes of high mobility group box 1 （HMGB1）,glutathione peroxidase（GPX3） in thyroid carcinoma and thier relationship with pathological characteristics. Methods The levels of HMGB1 and GPX3 were detected by using ELISA in 153 cases of thyroid cancer, 120 cases of benign thyroid nodules and 120 healthy controls. The changes of HMGB1 and GPX3 in the patients with thyroid cancer were analyzed. Their application value in thyroid cancer was analyzed by using the receiver operating characteristic（ROC） curve. Results The plasma HMGB1 level and the HMGB1 positive expression rate in the thyroid cancer group were higher than those in the benign thyroid nodules group and control group（P^0.05）, while the plas- ma GPX3 level and GPX3 positive expression rate in the thyroid cancer group were lower than those in the benign thyroid nodules group and control group（P〈0.05）. There were no significant differences in the levels of plasma HMGB1, GPX3 and the positive rates of HMGB1 and GPX3 between the thyroid benign nodule group and the healthy control group （P〉0. 05）. The plasma HMGB1 expression in thyroid cancer was closely related with the infiltration degree,clinical stage and lymph node metastasis（P〈0.05） ,and the GPX3 expression was related with the tumor stage and lymph node metastasis（P〈0.05）. The ROC curve showed that the sensitivity and specificity of HMGB1 and GPX3 for diagnosing thyroid cancer were 76.3% and 85.5 %, 70.8 % and 82.2 respectively. Conclusion Plasma HMGB1 and GPX3 expression levels are closely associated with the occurrence and progression of thyroid cancer.